Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events

The growth of rat hepatoma 7288CTC in vivo is stimulated by the uptake of linoleic acid (LA) and its metabolism to 13-hydroxyoctadecadienoic acid (13-HODE), an important mitogenic signaling molecule within this tumor. Conversely, the growth of a variety of experimental cancers in vivo is inhibited b...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer research (Chicago, Ill.) Ill.), 1999-09, Vol.59 (18), p.4693-4701
Hauptverfasser: BLASK, D. E, SAUER, L. A, DAUCHY, R. T, HOLOWACHUK, E. W, RUHOFF, M. S, KOPFF, H. S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4701
container_issue 18
container_start_page 4693
container_title Cancer research (Chicago, Ill.)
container_volume 59
creator BLASK, D. E
SAUER, L. A
DAUCHY, R. T
HOLOWACHUK, E. W
RUHOFF, M. S
KOPFF, H. S
description The growth of rat hepatoma 7288CTC in vivo is stimulated by the uptake of linoleic acid (LA) and its metabolism to 13-hydroxyoctadecadienoic acid (13-HODE), an important mitogenic signaling molecule within this tumor. Conversely, the growth of a variety of experimental cancers in vivo is inhibited by either physiological or pharmacological levels of the pineal gland hormone melatonin, although the mechanism(s) are unknown. We tested the hypothesis that the mechanism of melatonin's anticancer action in vivo involves the inhibition of tumor LA uptake and metabolism to 13-HODE in hepatoma 7288CTC. Tumor uptake of LA and release of 13-HODE, measured in tissue-isolated rat hepatoma 7288CTC at 4-h intervals over a 24-h period, were highest during the light phase and lowest during the mid-dark phase, when plasma melatonin levels were lowest and highest, respectively. Pinealectomy eliminated this rhythm of tumor LA uptake and 13-HODE production, indicating that it was driven by the circadian melatonin rhythm. Perfusion of tissue-isolated tumors in situ with melatonin (1 nM) rapidly and reversibly inhibited the uptake of plasma fatty acids (FAs), including LA, and its metabolism to 13-HODE. These inhibitory effects of melatonin on tumor FA uptake and 13-HODE release were completely reversed by perfusion of tumors in situ with melatonin receptor antagonist S-20928, pertussis toxin, forskolin, or 8-bromo-cAMP. Perfusion of tumors in situ with melatonin also decreased tumor [3H]thymidine incorporation and DNA content; these effects on DNA synthesis were also prevented by the coperfusion of tumors with melatonin and S-20928, pertussis toxin, forskolin, 8-Br-cAMP, or 13-HODE. Pinealectomy stimulated tumor growth, LA uptake and metabolism to 13-HODE, and FA storage in hepatoma 7288CTC, whereas melatonin administration (200 microg/day) was inhibitory in vivo. Northern blot analysis revealed that, compared with normal liver tissue, hepatoma 7288CTC overexpressed mRNA transcripts for a plasma membrane-associated FA transport protein (FATP). FATP mRNA expression was unaffected by the treatment of tumor-bearing rats with daily afternoon melatonin injections or exposure to constant light. These results support a novel mechanism of tumor growth inhibition by melatonin involving a melatonin receptor-mediated suppression of cAMP levels, resulting in diminished tumor FA transport, possibly via decreased FATP function. The inhibition of these signal transduction events by melatonin
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_70049993</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70049993</sourcerecordid><originalsourceid>FETCH-LOGICAL-h270t-8df43f3ca5d1cd979d02907de135042a964c3272ce6ad8a8047db09869df9e4e3</originalsourceid><addsrcrecordid>eNpFkN1KxDAQhYso7vrzCpIL8a6QNknTXMriH6x4o9fLbDJ1I21Sk7Tiu_iwBl3xajjMNzNnzkGxrARrS8m5OCyWlNK2FFzWi-IkxrcsRUXFcbGoKFdM1HJZfD1iD8k764h1O7u1yXpHfEc0OI2BvAb_kXa5R2Y7-1xn388YSZzGMWCMezpNgw-kg5Q-CWhryIAJtr63cciDkOXflYAax-RDOaCxkNCQaF8d9CQFcNFM-scAzuhSPCuOOugjnu_rafFye_O8ui_XT3cPq-t1uaslTWVrOs46pkGYShsllaG1otJgxQTlNaiGa1bLWmMDpoWWcmm2VLWNMp1Cjuy0uPrdOwb_PmFMm8FGjX0PDv0UN5LmvJRiGbzYg9M2-9-MwQ4QPjd_eWbgcg9A1NB3-Sdt4z-nGkVFw74BaDWEHw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70049993</pqid></control><display><type>article</type><title>Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>American Association for Cancer Research</source><creator>BLASK, D. E ; SAUER, L. A ; DAUCHY, R. T ; HOLOWACHUK, E. W ; RUHOFF, M. S ; KOPFF, H. S</creator><creatorcontrib>BLASK, D. E ; SAUER, L. A ; DAUCHY, R. T ; HOLOWACHUK, E. W ; RUHOFF, M. S ; KOPFF, H. S</creatorcontrib><description>The growth of rat hepatoma 7288CTC in vivo is stimulated by the uptake of linoleic acid (LA) and its metabolism to 13-hydroxyoctadecadienoic acid (13-HODE), an important mitogenic signaling molecule within this tumor. Conversely, the growth of a variety of experimental cancers in vivo is inhibited by either physiological or pharmacological levels of the pineal gland hormone melatonin, although the mechanism(s) are unknown. We tested the hypothesis that the mechanism of melatonin's anticancer action in vivo involves the inhibition of tumor LA uptake and metabolism to 13-HODE in hepatoma 7288CTC. Tumor uptake of LA and release of 13-HODE, measured in tissue-isolated rat hepatoma 7288CTC at 4-h intervals over a 24-h period, were highest during the light phase and lowest during the mid-dark phase, when plasma melatonin levels were lowest and highest, respectively. Pinealectomy eliminated this rhythm of tumor LA uptake and 13-HODE production, indicating that it was driven by the circadian melatonin rhythm. Perfusion of tissue-isolated tumors in situ with melatonin (1 nM) rapidly and reversibly inhibited the uptake of plasma fatty acids (FAs), including LA, and its metabolism to 13-HODE. These inhibitory effects of melatonin on tumor FA uptake and 13-HODE release were completely reversed by perfusion of tumors in situ with melatonin receptor antagonist S-20928, pertussis toxin, forskolin, or 8-bromo-cAMP. Perfusion of tumors in situ with melatonin also decreased tumor [3H]thymidine incorporation and DNA content; these effects on DNA synthesis were also prevented by the coperfusion of tumors with melatonin and S-20928, pertussis toxin, forskolin, 8-Br-cAMP, or 13-HODE. Pinealectomy stimulated tumor growth, LA uptake and metabolism to 13-HODE, and FA storage in hepatoma 7288CTC, whereas melatonin administration (200 microg/day) was inhibitory in vivo. Northern blot analysis revealed that, compared with normal liver tissue, hepatoma 7288CTC overexpressed mRNA transcripts for a plasma membrane-associated FA transport protein (FATP). FATP mRNA expression was unaffected by the treatment of tumor-bearing rats with daily afternoon melatonin injections or exposure to constant light. These results support a novel mechanism of tumor growth inhibition by melatonin involving a melatonin receptor-mediated suppression of cAMP levels, resulting in diminished tumor FA transport, possibly via decreased FATP function. The inhibition of these signal transduction events by melatonin culminates in the suppression of LA uptake, LA metabolism to the mitogenic signaling molecule 13-HODE, and cancer growth.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>PMID: 10493527</identifier><identifier>CODEN: CNREA8</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>8-Bromo Cyclic Adenosine Monophosphate - pharmacology ; Animals ; Antineoplastic agents ; Biological and medical sciences ; Biological Transport - drug effects ; Cell Division - drug effects ; Cell Division - physiology ; Chemotherapy ; Circadian Rhythm ; Colforsin - pharmacology ; Linoleic Acid - metabolism ; Linoleic Acids - metabolism ; Linoleic Acids - pharmacology ; Liver Neoplasms, Experimental - pathology ; Liver Neoplasms, Experimental - physiopathology ; Male ; Medical sciences ; Melatonin - pharmacology ; Models, Biological ; Naphthalenes - pharmacology ; Perfusion ; Pertussis Toxin ; Pharmacology. Drug treatments ; Rats ; Rats, Inbred BUF ; Receptors, Cell Surface - antagonists &amp; inhibitors ; Receptors, Cell Surface - physiology ; Receptors, Cytoplasmic and Nuclear - antagonists &amp; inhibitors ; Receptors, Cytoplasmic and Nuclear - physiology ; Receptors, Melatonin ; Signal Transduction - drug effects ; Signal Transduction - physiology ; Virulence Factors, Bordetella - pharmacology</subject><ispartof>Cancer research (Chicago, Ill.), 1999-09, Vol.59 (18), p.4693-4701</ispartof><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1969056$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10493527$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BLASK, D. E</creatorcontrib><creatorcontrib>SAUER, L. A</creatorcontrib><creatorcontrib>DAUCHY, R. T</creatorcontrib><creatorcontrib>HOLOWACHUK, E. W</creatorcontrib><creatorcontrib>RUHOFF, M. S</creatorcontrib><creatorcontrib>KOPFF, H. S</creatorcontrib><title>Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events</title><title>Cancer research (Chicago, Ill.)</title><addtitle>Cancer Res</addtitle><description>The growth of rat hepatoma 7288CTC in vivo is stimulated by the uptake of linoleic acid (LA) and its metabolism to 13-hydroxyoctadecadienoic acid (13-HODE), an important mitogenic signaling molecule within this tumor. Conversely, the growth of a variety of experimental cancers in vivo is inhibited by either physiological or pharmacological levels of the pineal gland hormone melatonin, although the mechanism(s) are unknown. We tested the hypothesis that the mechanism of melatonin's anticancer action in vivo involves the inhibition of tumor LA uptake and metabolism to 13-HODE in hepatoma 7288CTC. Tumor uptake of LA and release of 13-HODE, measured in tissue-isolated rat hepatoma 7288CTC at 4-h intervals over a 24-h period, were highest during the light phase and lowest during the mid-dark phase, when plasma melatonin levels were lowest and highest, respectively. Pinealectomy eliminated this rhythm of tumor LA uptake and 13-HODE production, indicating that it was driven by the circadian melatonin rhythm. Perfusion of tissue-isolated tumors in situ with melatonin (1 nM) rapidly and reversibly inhibited the uptake of plasma fatty acids (FAs), including LA, and its metabolism to 13-HODE. These inhibitory effects of melatonin on tumor FA uptake and 13-HODE release were completely reversed by perfusion of tumors in situ with melatonin receptor antagonist S-20928, pertussis toxin, forskolin, or 8-bromo-cAMP. Perfusion of tumors in situ with melatonin also decreased tumor [3H]thymidine incorporation and DNA content; these effects on DNA synthesis were also prevented by the coperfusion of tumors with melatonin and S-20928, pertussis toxin, forskolin, 8-Br-cAMP, or 13-HODE. Pinealectomy stimulated tumor growth, LA uptake and metabolism to 13-HODE, and FA storage in hepatoma 7288CTC, whereas melatonin administration (200 microg/day) was inhibitory in vivo. Northern blot analysis revealed that, compared with normal liver tissue, hepatoma 7288CTC overexpressed mRNA transcripts for a plasma membrane-associated FA transport protein (FATP). FATP mRNA expression was unaffected by the treatment of tumor-bearing rats with daily afternoon melatonin injections or exposure to constant light. These results support a novel mechanism of tumor growth inhibition by melatonin involving a melatonin receptor-mediated suppression of cAMP levels, resulting in diminished tumor FA transport, possibly via decreased FATP function. The inhibition of these signal transduction events by melatonin culminates in the suppression of LA uptake, LA metabolism to the mitogenic signaling molecule 13-HODE, and cancer growth.</description><subject>8-Bromo Cyclic Adenosine Monophosphate - pharmacology</subject><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Biological Transport - drug effects</subject><subject>Cell Division - drug effects</subject><subject>Cell Division - physiology</subject><subject>Chemotherapy</subject><subject>Circadian Rhythm</subject><subject>Colforsin - pharmacology</subject><subject>Linoleic Acid - metabolism</subject><subject>Linoleic Acids - metabolism</subject><subject>Linoleic Acids - pharmacology</subject><subject>Liver Neoplasms, Experimental - pathology</subject><subject>Liver Neoplasms, Experimental - physiopathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Melatonin - pharmacology</subject><subject>Models, Biological</subject><subject>Naphthalenes - pharmacology</subject><subject>Perfusion</subject><subject>Pertussis Toxin</subject><subject>Pharmacology. Drug treatments</subject><subject>Rats</subject><subject>Rats, Inbred BUF</subject><subject>Receptors, Cell Surface - antagonists &amp; inhibitors</subject><subject>Receptors, Cell Surface - physiology</subject><subject>Receptors, Cytoplasmic and Nuclear - antagonists &amp; inhibitors</subject><subject>Receptors, Cytoplasmic and Nuclear - physiology</subject><subject>Receptors, Melatonin</subject><subject>Signal Transduction - drug effects</subject><subject>Signal Transduction - physiology</subject><subject>Virulence Factors, Bordetella - pharmacology</subject><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkN1KxDAQhYso7vrzCpIL8a6QNknTXMriH6x4o9fLbDJ1I21Sk7Tiu_iwBl3xajjMNzNnzkGxrARrS8m5OCyWlNK2FFzWi-IkxrcsRUXFcbGoKFdM1HJZfD1iD8k764h1O7u1yXpHfEc0OI2BvAb_kXa5R2Y7-1xn388YSZzGMWCMezpNgw-kg5Q-CWhryIAJtr63cciDkOXflYAax-RDOaCxkNCQaF8d9CQFcNFM-scAzuhSPCuOOugjnu_rafFye_O8ui_XT3cPq-t1uaslTWVrOs46pkGYShsllaG1otJgxQTlNaiGa1bLWmMDpoWWcmm2VLWNMp1Cjuy0uPrdOwb_PmFMm8FGjX0PDv0UN5LmvJRiGbzYg9M2-9-MwQ4QPjd_eWbgcg9A1NB3-Sdt4z-nGkVFw74BaDWEHw</recordid><startdate>19990915</startdate><enddate>19990915</enddate><creator>BLASK, D. E</creator><creator>SAUER, L. A</creator><creator>DAUCHY, R. T</creator><creator>HOLOWACHUK, E. W</creator><creator>RUHOFF, M. S</creator><creator>KOPFF, H. S</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19990915</creationdate><title>Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events</title><author>BLASK, D. E ; SAUER, L. A ; DAUCHY, R. T ; HOLOWACHUK, E. W ; RUHOFF, M. S ; KOPFF, H. S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h270t-8df43f3ca5d1cd979d02907de135042a964c3272ce6ad8a8047db09869df9e4e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>8-Bromo Cyclic Adenosine Monophosphate - pharmacology</topic><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Biological Transport - drug effects</topic><topic>Cell Division - drug effects</topic><topic>Cell Division - physiology</topic><topic>Chemotherapy</topic><topic>Circadian Rhythm</topic><topic>Colforsin - pharmacology</topic><topic>Linoleic Acid - metabolism</topic><topic>Linoleic Acids - metabolism</topic><topic>Linoleic Acids - pharmacology</topic><topic>Liver Neoplasms, Experimental - pathology</topic><topic>Liver Neoplasms, Experimental - physiopathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Melatonin - pharmacology</topic><topic>Models, Biological</topic><topic>Naphthalenes - pharmacology</topic><topic>Perfusion</topic><topic>Pertussis Toxin</topic><topic>Pharmacology. Drug treatments</topic><topic>Rats</topic><topic>Rats, Inbred BUF</topic><topic>Receptors, Cell Surface - antagonists &amp; inhibitors</topic><topic>Receptors, Cell Surface - physiology</topic><topic>Receptors, Cytoplasmic and Nuclear - antagonists &amp; inhibitors</topic><topic>Receptors, Cytoplasmic and Nuclear - physiology</topic><topic>Receptors, Melatonin</topic><topic>Signal Transduction - drug effects</topic><topic>Signal Transduction - physiology</topic><topic>Virulence Factors, Bordetella - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BLASK, D. E</creatorcontrib><creatorcontrib>SAUER, L. A</creatorcontrib><creatorcontrib>DAUCHY, R. T</creatorcontrib><creatorcontrib>HOLOWACHUK, E. W</creatorcontrib><creatorcontrib>RUHOFF, M. S</creatorcontrib><creatorcontrib>KOPFF, H. S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BLASK, D. E</au><au>SAUER, L. A</au><au>DAUCHY, R. T</au><au>HOLOWACHUK, E. W</au><au>RUHOFF, M. S</au><au>KOPFF, H. S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><addtitle>Cancer Res</addtitle><date>1999-09-15</date><risdate>1999</risdate><volume>59</volume><issue>18</issue><spage>4693</spage><epage>4701</epage><pages>4693-4701</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><coden>CNREA8</coden><abstract>The growth of rat hepatoma 7288CTC in vivo is stimulated by the uptake of linoleic acid (LA) and its metabolism to 13-hydroxyoctadecadienoic acid (13-HODE), an important mitogenic signaling molecule within this tumor. Conversely, the growth of a variety of experimental cancers in vivo is inhibited by either physiological or pharmacological levels of the pineal gland hormone melatonin, although the mechanism(s) are unknown. We tested the hypothesis that the mechanism of melatonin's anticancer action in vivo involves the inhibition of tumor LA uptake and metabolism to 13-HODE in hepatoma 7288CTC. Tumor uptake of LA and release of 13-HODE, measured in tissue-isolated rat hepatoma 7288CTC at 4-h intervals over a 24-h period, were highest during the light phase and lowest during the mid-dark phase, when plasma melatonin levels were lowest and highest, respectively. Pinealectomy eliminated this rhythm of tumor LA uptake and 13-HODE production, indicating that it was driven by the circadian melatonin rhythm. Perfusion of tissue-isolated tumors in situ with melatonin (1 nM) rapidly and reversibly inhibited the uptake of plasma fatty acids (FAs), including LA, and its metabolism to 13-HODE. These inhibitory effects of melatonin on tumor FA uptake and 13-HODE release were completely reversed by perfusion of tumors in situ with melatonin receptor antagonist S-20928, pertussis toxin, forskolin, or 8-bromo-cAMP. Perfusion of tumors in situ with melatonin also decreased tumor [3H]thymidine incorporation and DNA content; these effects on DNA synthesis were also prevented by the coperfusion of tumors with melatonin and S-20928, pertussis toxin, forskolin, 8-Br-cAMP, or 13-HODE. Pinealectomy stimulated tumor growth, LA uptake and metabolism to 13-HODE, and FA storage in hepatoma 7288CTC, whereas melatonin administration (200 microg/day) was inhibitory in vivo. Northern blot analysis revealed that, compared with normal liver tissue, hepatoma 7288CTC overexpressed mRNA transcripts for a plasma membrane-associated FA transport protein (FATP). FATP mRNA expression was unaffected by the treatment of tumor-bearing rats with daily afternoon melatonin injections or exposure to constant light. These results support a novel mechanism of tumor growth inhibition by melatonin involving a melatonin receptor-mediated suppression of cAMP levels, resulting in diminished tumor FA transport, possibly via decreased FATP function. The inhibition of these signal transduction events by melatonin culminates in the suppression of LA uptake, LA metabolism to the mitogenic signaling molecule 13-HODE, and cancer growth.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>10493527</pmid><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0008-5472
ispartof Cancer research (Chicago, Ill.), 1999-09, Vol.59 (18), p.4693-4701
issn 0008-5472
1538-7445
language eng
recordid cdi_proquest_miscellaneous_70049993
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; American Association for Cancer Research
subjects 8-Bromo Cyclic Adenosine Monophosphate - pharmacology
Animals
Antineoplastic agents
Biological and medical sciences
Biological Transport - drug effects
Cell Division - drug effects
Cell Division - physiology
Chemotherapy
Circadian Rhythm
Colforsin - pharmacology
Linoleic Acid - metabolism
Linoleic Acids - metabolism
Linoleic Acids - pharmacology
Liver Neoplasms, Experimental - pathology
Liver Neoplasms, Experimental - physiopathology
Male
Medical sciences
Melatonin - pharmacology
Models, Biological
Naphthalenes - pharmacology
Perfusion
Pertussis Toxin
Pharmacology. Drug treatments
Rats
Rats, Inbred BUF
Receptors, Cell Surface - antagonists & inhibitors
Receptors, Cell Surface - physiology
Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors
Receptors, Cytoplasmic and Nuclear - physiology
Receptors, Melatonin
Signal Transduction - drug effects
Signal Transduction - physiology
Virulence Factors, Bordetella - pharmacology
title Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T09%3A58%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Melatonin%20inhibition%20of%20cancer%20growth%20in%20vivo%20involves%20suppression%20of%20tumor%20fatty%20acid%20metabolism%20via%20melatonin%20receptor-mediated%20signal%20transduction%20events&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=BLASK,%20D.%20E&rft.date=1999-09-15&rft.volume=59&rft.issue=18&rft.spage=4693&rft.epage=4701&rft.pages=4693-4701&rft.issn=0008-5472&rft.eissn=1538-7445&rft.coden=CNREA8&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E70049993%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70049993&rft_id=info:pmid/10493527&rfr_iscdi=true